Endometrial Cancer

>

Latest News

Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in Endometrial Cancer
Lenvatinib-Pembrolizumab Duo Delivers Impressive Results in Endometrial Cancer

September 18th 2024

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.

Adjuvant Pembrolizumab/Chemotherapy Fails to Improve DFS High-Risk Endometrial Cancer
Adjuvant Pembrolizumab/Chemotherapy Fails to Improve DFS High-Risk Endometrial Cancer

September 14th 2024

FDA Expands Dostarlimab Approval for All Advanced Endometrial Cancers
FDA Expands Dostarlimab Approval for All Advanced Endometrial Cancers

August 1st 2024

Endometrial Cancer Treatment: A Shift Towards Personalized Care
Endometrial Cancer Treatment: A Shift Towards Personalized Care

July 24th 2024

Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer

July 23rd 2024